Atezolizumab 和 Tiragolumab 与 Durvalumab 在局部晚期、不可切除的 III 期非小细胞肺癌 (NSCLC) 参与者中的比较研究 (SKYSCRAPER-03)
2026年5月7日 更新者:Hoffmann-La Roche
一项 III 期、开放标签、随机研究,比较 Atezolizumab 和 Tiragolumab 与 Durvalumab 在接受铂类放化疗后未进展的局部晚期、不可切除的 III 期非小细胞肺癌患者中的疗效
本研究的目的是评估 atezolizumab 联合 tiragolumab 与 durvalumab 相比在局部晚期、不可切除的 III 期非小细胞肺癌 (NSCLC) 参与者中的疗效和安全性,这些患者已接受至少两个周期的同步铂-基于化放疗 (CRT) 且未出现影像学疾病进展。
研究概览
研究类型
介入性
注册 (实际的)
829
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Beijing、中国、101149
- Beijing Chest Hospital
-
Beijing、中国、100142
- Beijing Cancer Center
-
Changchun、中国、132013
- Jilin cancer hospital
-
Changsha、中国、410008
- Xiangya Hospital Central South University
-
Chengdu、中国、610041
- Sichuan Provincial Cancer Hospital
-
Chongqing、中国、400030
- Chongqing Cancer Hospital
-
Fujian、中国、350001
- Fujian Medical University Union Hospital
-
Fuzhou、中国、350014
- Fujian Provincial Cancer Hospital
-
Guangzhou、中国、510060
- Cancer Center, Sun Yat-sen University of Medical Sciences
-
Hangzhou、中国、310002
- Hangzhou Cancer Hospital
-
Jinan、中国、250117
- Shandong Cancer Hospital
-
Nanjing、中国、210009
- Zhongda Hospital Affiliated to Southeast University
-
Qingdao、中国、266042
- The Affiliated Hospital of Qingdao University
-
Shanghai、中国、200000
- Shanghai Chest Hospital
-
Shantou、中国、515041
- Cancer Hospital of Shantou University Medical College
-
Taiyuan、中国、030013
- Shanxi Provincial Cancer Hospital
-
Tianjin、中国、300060
- Tianjin Cancer Hospital
-
Wenzhou、中国、325000
- The 2nd School of Medicine, WMU
-
Xiamen、中国、361003
- The First Affiliated Hospital of Xiamen University
-
Xuzhou、中国、221000
- The Affiliated Hospital of Xuzhou Medical College
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Beersheba、以色列、8410100
- Soroka Medical Center
-
Haifa、以色列、3109601
- Rambam Medical Center
-
Jerusalem、以色列、9103102
- Shaare Zedek Medical Center
-
Petah Tikva、以色列、4941492
- Rabin Medical Center
-
-
-
-
British Columbia
-
Abbotsford British Columbia、British Columbia、加拿大、V2S 0C2
- BC Cancer ? Abbotsford
-
Victoria、British Columbia、加拿大、V8R 6V5
- BC Cancer - Victoria
-
-
Ontario
-
Barrie、Ontario、加拿大、L4M 6M2
- Royal Victoria Regional Health Centre
-
Brampton、Ontario、加拿大、L6R 3J7
- William Osler Health System Brampton Civic Hospital
-
Ottawa、Ontario、加拿大、K1H 8L6
- Ottawa Hospital Research Institute
-
-
-
-
-
Pécs、匈牙利、7623
- Pecsi Tudomanyegyetem
-
Tatabánya、匈牙利、2800
- Szent Borbala Korhaz
-
Törökbálint、匈牙利、2045
- Tudogyogyintezet Torokbalint
-
-
-
-
-
Taichung、台湾、40447
- China Medical University Hospital
-
Taipei、台湾、112
- Taipei Veterans General Hospital
-
-
-
-
-
Adana、土耳其(türkiye)、01220
- Adana Baskent University Medical Faculty
-
Ankara、土耳其(türkiye)、06500
- Gazi University Medical Faculty, Oncology Hospital
-
Ankara、土耳其(türkiye)、06100
- Ankara University Medical Faculty
-
Ankara、土耳其(türkiye)、06100
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Bornova, ?zm?r、土耳其(türkiye)、35100
- Ege University Medical Faculty
-
Diyarbakır、土耳其(türkiye)、21280
- Dicle University Faculty of Medicine
-
Edirne、土耳其(türkiye)、22030
- Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
-
Istanbul、土耳其(türkiye)、34098
- Istanbul University Cerrahpasa Faculty of Medicine
-
Istanbul、土耳其(türkiye)、34214
- Medipol University Medical Faculty
-
Malatya、土耳其(türkiye)、44280
- Inonu University Faculty of Medicine Turgut Ozal Medical Center
-
-
-
-
-
Innsbruck、奥地利、6020
- Tiroler Landeskrankenanstalten Ges.M.B.H.
-
Linz、奥地利、4020
- Kepler Universitätskliniken GmbH - Med Campus III
-
Vienna、奥地利、1140
- Klinik Penzing
-
-
-
-
Ceará
-
Fortaleza、Ceará、巴西、60336-550
- CRIO - Centro Regional Integrado de Oncologia
-
-
Paraná
-
Curitiba、Paraná、巴西、80810-050
- Centro Integrado de Oncologia de Curitiba
-
-
Rio Grande do Sul
-
Ijuí、Rio Grande do Sul、巴西、98700-000
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
-
Porto Alegre、Rio Grande do Sul、巴西、90610-000
- Hospital Sao Lucas - PUCRS
-
-
São Paulo
-
Barretos、São Paulo、巴西、14784-400
- Hospital de Cancer de Barretos
-
São José do Rio Preto、São Paulo、巴西、15090-000
- Hospital de Base de Sao Jose do Rio Preto
-
São Paulo、São Paulo、巴西、01246-000
- Instituto do Câncer do Estado de São Paulo - ICESP
-
-
-
-
-
Asvestochóri、希腊、570 10
- General Hospital "G.Papanikolaou"
-
Athens、希腊、11527
- Sotiria Hospital
-
Kifissia、希腊、145 64
- Agioi Anargyroi Cancer Hospital
-
-
-
-
-
Braunschweig、德国、38114
- Klinikum Braunschweig
-
Cologne、德国、51109
- Klinikum Koeln-Merheim
-
Göttingen、德国、37075
- Universitaetsmedizin Goettingen
-
Heidelberg、德国、69126
- Thoraxklinik Heidelberg gGmbH
-
München、德国、81925
- Klinikum Bogenhausen
-
Regensburg、德国、93053
- Universitätsklinikum Regensburg
-
-
-
-
Campania
-
Naples、Campania、意大利、80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
-
-
Emilia-Romagna
-
Meldola、Emilia-Romagna、意大利、47014
- IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
-
Parma、Emilia-Romagna、意大利、43100
- Azienda Ospedaliero Universitaria di Parma
-
-
Lazio
-
Rome、Lazio、意大利、00128
- Policlinico Universitario Campus Biomedico
-
Rome、Lazio、意大利、00144
- IRCCS Istituto Regina Elena (IFO)
-
-
Liguria
-
Genoa、Liguria、意大利、16132
- IRCCS AOU San Martino - IST
-
-
Lombardy
-
Brescia、Lombardy、意大利、25123
- A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
-
Milan、Lombardy、意大利、DUMMY_VALUE
- Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
-
Pavia、Lombardy、意大利、27100
- Fondazione IRCCS Policlinico San Matteo
-
-
Tuscany
-
Pisa、Tuscany、意大利、56124
- Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello
-
-
Veneto
-
Vicenza、Veneto、意大利、36100
- Azienda ULSS 8 Berica
-
-
-
-
-
Auckland、新西兰、1023
- Auckland City Hospital, Cancer and Blood Research
-
-
-
-
-
Aichi、日本、464-8681
- Aichi Cancer Center
-
Chiba、日本、277-8577
- National Cancer Center East
-
Hyōgo、日本、670-8520
- National Hospital Organization Himeji Medical Center
-
Kanagawa、日本、252-0375
- Kitasato University Hospital
-
Kyoto、日本、606-8507
- Kyoto University Hospital
-
Miyagi、日本、981-0914
- Sendai Kousei Hospital
-
Niigata、日本、951-8566
- Niigata Cancer Center Hospital
-
Osaka、日本、589-8511
- Kindai University Hospital
-
Saitama、日本、362-0806
- Saitama Cancer Center
-
Shizuoka、日本、411-8777
- Shizuoka Cancer Center
-
Tokyo、日本、104-0045
- National Cancer Center Hospital
-
Tokyo、日本、135-8550
- The Cancer Institute Hospital of JFCR
-
Wakayama、日本、641-8510
- Wakayama Medical University Hospital
-
-
-
-
-
Charleroi、比利时、6000
- GHdC Site Les Viviers
-
Ghent、比利时、9000
- AZ Maria Middelares
-
Hasselt、比利时、3500
- Jessa Zkh (Campus Virga Jesse)
-
-
-
-
-
Angers、法国、49933
- CHU Angers
-
Caen、法国、14000
- Centre François Baclesse
-
Marseille、法国、13015
- Hopital Nord AP-HM
-
Montpellier、法国、34070
- Clinique Clementville
-
Vantoux、法国、57070
- Hôpital Robert Schuman
-
Villejuif、法国、94805
- Institut Gustave Roussy
-
-
-
-
-
Gda?sk、波兰、80-214
- Uniwersyteckie Centrum Kliniczne
-
Olsztyn、波兰、10-228
- Szpital Kliniczny MSWiA z Warmi?sko-Mazurskim Centrum Onkologii
-
Otwock、波兰、05-400
- Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
-
Warsaw、波兰、02-781
- Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
-
Wroc?aw、波兰、53-413
- Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii
-
-
-
-
-
Bangkok、泰国、10400
- Rajavithi Hospital
-
Bangkok、泰国、10300
- Vajira Hospital
-
Bangkok、泰国、10400
- Ramathibodi Hospital;Medicine/Oncology
-
Songkhla、泰国、90110
- Songklanagarind Hospital
-
-
-
-
New South Wales
-
Blacktown、New South Wales、澳大利亚、2148
- Blacktown Hospital
-
Campbelltown、New South Wales、澳大利亚、2560
- Macarthur Cancer Therapy Centre
-
Kogarah、New South Wales、澳大利亚、2217
- St George Hospital
-
-
South Australia
-
Bedford Park、South Australia、澳大利亚、5042
- Flinders Medical Centre
-
-
Victoria
-
Victoria、Victoria、澳大利亚、3168
- Monash Health Translational Precinct
-
-
Western Australia
-
Bull Creek、Western Australia、澳大利亚、6149
- Fiona Stanley Hospital
-
-
-
-
California
-
Palo Alto、California、美国、94305
- Stanford University
-
-
Colorado
-
Greeley、Colorado、美国、80631
- Banner MD Anderson Cancer Center
-
-
Florida
-
Fort Myers、Florida、美国、33901-8101
- Florida Cancer Specialists
-
Palm Bay、Florida、美国、32901
- Cancer Care Centers of Brevard
-
Pensacola、Florida、美国、32503
- Woodlands Medical Specialists, P.A.
-
St. Petersburg、Florida、美国、33705
- Florida Cancer Specialist, North Region
-
-
Georgia
-
Marietta、Georgia、美国、30060
- Northwest Georgia Oncology Centers PC - Marietta
-
-
Illinois
-
Peoria、Illinois、美国、61615
- Illinois Cancer Care
-
-
Maine
-
Brunswick、Maine、美国、04011
- New England Cancer Specialists
-
-
Massachusetts
-
Fairhaven、Massachusetts、美国、02719
- Southcoast Health System
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55404
- Minnesota Oncology Hematology
-
-
Missouri
-
Kansas City、Missouri、美国、64132
- HCA Midwest Health
-
Springfield、Missouri、美国、65807
- Cox Health Systems
-
-
Nevada
-
Las Vegas、Nevada、美国、89128
- Comprehensive Cancer Centers of Nevada
-
Las Vegas、Nevada、美国、89106
- Optum Health Care
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- Titan Health Partners LLC, d/b/a Astera Cancer Care
-
-
New Mexico
-
Farmington、New Mexico、美国、87401
- San Juan Oncology Associates
-
-
New York
-
Albany、New York、美国、12208
- New York Oncology Hematology,P.C.-Albany
-
New York、New York、美国、10029
- Mount Sinai Medical Center
-
The Bronx、New York、美国、10461
- Montefiore Medical Center
-
-
South Carolina
-
Greenville、South Carolina、美国、29615
- Prisma Health ? Upstate
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37403
- Tennessee Oncology Chattanooga
-
Nashville、Tennessee、美国、37203
- Sarah Cannon Research Institute / Tennessee Oncology
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- Virginia Cancer Specialists
-
Norfolk、Virginia、美国、23502
- Virginia Oncology Associates
-
-
-
-
-
Birmingham、英国、B9 5SS
- Birmingham Heartlands Hospital
-
Cambridge、英国、CB2 0QQ
- Addenbrooke's NHS Trust
-
Glasgow、英国、G12 0YN
- Beatson West of Scotland Cancer Centre
-
Huddersfield、英国、HD3 3EA
- Calderdale & Huddersfield Nhs Trust
-
Leicester、英国、LE1 5WW
- Leicester Royal Infirmary
-
Maidstone、英国、ME16 9QQ
- Maidstone & Tonbridge Wells Hospital
-
Manchester、英国、M20 4BX
- Christie Foundation Trust
-
Sheffield、英国、S10 2SJ
- Weston Park Hospital
-
-
-
-
-
Amersfoort、荷兰、3813 TZ
- Meander Medisch Centrum
-
Breda、荷兰、4819 EV
- Amphia Ziekenhuis
-
Leidschendam、荷兰、2262 BA
- Medisch Centrum Haaglanden, locatie Antoniushove
-
Sittard-Geleen、荷兰、6162 BG
- Zuyderland Medisch Centrum - Sittard Geleen
-
-
-
-
-
Coimbra、葡萄牙、3000-075
- IPO de Coimbra
-
Lisbon、葡萄牙、1500-650
- Hospital da Luz
-
Porto、葡萄牙、4100-180
- Hospital CUF Porto
-
Porto、葡萄牙、4200-072
- IPO do Porto
-
-
-
-
-
A Coruña、西班牙、15006
- Complejo Hospitalario Universitario A Coruña (CHUAC)
-
Barcelona、西班牙、08035
- Hospital Universitari Vall d'Hebron
-
Madrid、西班牙、28041
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙、28046
- Hospital Universitario La Paz
-
Madrid、西班牙、28009
- Hospital General Universitario Gregorio Marañón
-
Málaga、西班牙、29010
- Hospital Regional Universitario Carlos Haya
-
Seville、西班牙、41013
- Hospital Universitario Virgen del Rocío
-
Seville、西班牙、41014
- Hospital Univ. Nuestra Señora de Valme
-
-
Balearic Islands
-
Palma de Mallorca、Balearic Islands、西班牙、07198
- Hospital Son Llatzer
-
-
Barcelona
-
Badalona、Barcelona、西班牙、08916
- Hospital Universitari Germans Trias i Pujol
-
-
Castellon
-
Castellon、Castellon、西班牙、12002
- Hospital Provincial de Castellon
-
-
-
-
-
Buenos Aires、阿根廷、C1431FWO
- CEMIC
-
Ciudad Autonoma Buenos Aires、阿根廷、C1284AEB
- Hospital Británico de Buenos Aires
-
Córdoba、阿根廷、X5004FHP
- Clínica Universitaria Reina Fabiola
-
Rosario、阿根廷、S2000QGB
- Sanatorio Parque S.A.
-
-
-
-
-
Cheongju-si、韩国、28644
- Chungbuk National University Hospital
-
Daegu、韩国、41404
- Kyungpook National University Chilgok Hospital
-
Gyeonggi-do、韩国、13620
- Seoul National University Bundang Hospital
-
Gyeonggi-do、韩国、16247
- St. Vincent's Hospital
-
Gyeonggi-do、韩国、10408
- National Cancer Center
-
Gyeonggi-do、韩国、16499
- Ajou University Medical Center
-
Gyeongsangnam-do、韩国、50612
- Pusan National University Yangsan Hospital
-
Incheon、韩国、21565
- Gachon University Gil Medical Center
-
Jeollanam-do、韩国、58128
- Chonnam National University Hwasun Hospital
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、06351
- Samsung Medical Center
-
Seoul、韩国、08308
- Korea University Guro Hospital
-
Seoul、韩国、06591
- Seoul St Mary's Hospital
-
Ulsan、韩国、44033
- Ulsan University Hosiptal
-
-
-
-
-
Hong Kong、香港
- Tuen Mun Hospital
-
Hong Kong、香港
- Pamela Youde Nethersole Eastern Hospital
-
Hong Kong、香港、DUMMY_VALUE
- Queen Elizabeth Hospital
-
Hong Kong、香港、DUMMY_VALUE
- Princess Margaret Hospital, Oncology
-
Pokfulam、香港、DUMMY_VALUE
- Queen Mary Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
描述
纳入标准:
- 东部肿瘤合作组 (ECOG) 绩效状态为 0 或 1
- 组织学或细胞学证实为鳞状或非鳞状组织学的局部晚期、不可切除的 III 期 NSCLC
- 全身正电子发射断层扫描-计算机断层扫描 (PET-CT),在同步放化疗 (cCRT) 第一剂之前和 42 天内进行
- 至少两个先前周期的铂类化疗与放疗 (RT) 同时进行,必须在研究随机分组前 1 至 42 天内完成(一个周期的 cCRT 定义为 21 或 28 天)
- cCRT 中的放疗 (RT) 成分必须已达到 60(±10% [%])戈瑞 (Gy)(54 Gy 至 66 Gy)的总辐射剂量,由强度调制 RT(首选)或 3D-符合技术
- 在同时进行的基于铂的 CRT 期间或之后没有进展
- 已知的 PD-L1 结果
- 预期寿命 >/= 12 周
- 足够的血液学和终末器官功能
- 女性参与者必须愿意在 tiragolumab 的最后一剂后 90 天和 atezolizumab 的最后一剂后 5 个月或 durvalumab 的最后一剂后 3 个月内避免怀孕
- 男性参与者必须在治疗期间和 tiragolumab 最后一次给药后 90 天内保持禁欲或使用避孕套
- 男性参与者在治疗期间和 tiragolumab 最后一次给药后 90 天内不得捐献精子
排除标准:
- 任何既往 NSCLC 病史和/或任何 NSCLC 既往治疗史(参与者必须是新诊断出患有不可切除的 III 期疾病)
- 已知具有表皮生长因子受体 (EGFR) 基因突变或间变性淋巴瘤激酶 (ALK) 融合致癌基因的 NSCLC
- IV 期疾病的任何证据
- 序贯 CRT 治疗局部晚期 NSCLC
- 在随机化之前在最终 cCRT 期间或之后取得进展的局部晚期 NSCLC 参与者
- 先前 CRT 的任何 >2 级未解决的毒性
- 来自先前 CRT 的 >= 2 级肺炎
- 自身免疫性疾病或免疫缺陷的活动或病史
- 特发性肺纤维化、机化性肺炎、药物性肺炎或特发性肺炎病史或活动性肺炎的证据
- 筛查前 5 年内非小细胞肺癌以外的恶性肿瘤病史,但转移或死亡风险可忽略不计的恶性肿瘤除外
- 先前的同种异体干细胞或实体器官移植
- 筛选时活动性 Epstein-Barr 病毒 (EBV) 感染或已知或疑似慢性活动性 EBV 感染
- 研究治疗开始前 28 天内接受研究性治疗
- 先前使用 CD137 激动剂或免疫检查点阻断疗法进行治疗,包括抗细胞毒性 T 淋巴细胞相关蛋白 4、具有 Ig 和 ITIM 结构域的抗 T 细胞免疫受体(抗 TIGIT)、抗 PD-1 和抗 PD-L1
- 在接受除免疫检查点阻断剂以外的任何既往免疫治疗药物时,任何先前 >/= 3 级免疫介导的不良事件或任何未解决的 > 1 级免疫介导的不良事件
- 全身免疫抑制药物治疗
- 怀孕或哺乳的妇女
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:阿特朱单抗 + 替拉戈单抗
参与者将在每个 28 天周期的第 1 天接受静脉注射 (IV) atezolizumab,然后在每个 28 天周期的第 1 天接受 tiragolumab 静脉注射,最多 13 个周期。
|
Atezolizumab 1680 mg 每 4 周 (Q4W) 将在每个 28 天周期的第 1 天静脉注射。
其他名称:
Tiragolumab 840 mg Q4W 将在每个 28 天周期的第 1 天静脉注射。
其他名称:
|
|
有源比较器:度伐单抗
参与者将在每个 28 天的周期内接受最多 13 个周期的 durvalumab 静脉注射。
|
Durvalumab 将在每个 28 天周期的第 1 天和第 15 天每 2 周(Q2W)根据体重以 10 mg/kg IV 给药,或者将以每 4 周(Q4W)1500 mg IV 的固定剂量给药(对于体重 >/= 30 公斤的参与者)在每个 28 天周期的第 1 天。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions.
Kaplan-Meier (K-M) method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
PFS, as Assessed by an IRF in FAS
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS) in PPAS
大体时间:From randomization to death from any cause (up to approximately 57 months)
|
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate median OS.
|
From randomization to death from any cause (up to approximately 57 months)
|
|
PFS, as Assessed by the Investigator in PPAS
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
Confirmed Objective Response Rate (ORR), as Assessed by an IRF in PPAS
大体时间:Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an objective response (OR), characterized by a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by an IRF according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesion & normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
Confirmed ORR, as Assessed by the Investigator in PPAS
大体时间:Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an OR, characterized by CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesions & normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
Duration of Response (DOR), as Assessed by an IRF in PPAS
大体时间:From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions & normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
DOR, as Assessed by the Investigator in PPAS
大体时间:From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
Time to Confirmed Deterioration (TTCD) in Cough, as Assessed Using European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) in PPAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first confirmed clinically meaningful deterioration (CCMD) on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Cough scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Dyspnoea, as Assessed Using EORTC QLQ-LC13 in PPAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Dyspnoea was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Chest Pain, as Assessed Using EORTC QLQ-LC13 in PPAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Chest pain was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Global Health Status (GHS)/Quality-of-life (QoL), as Assessed Using European Organisation for Research and Treatment of Cancer Quality-of-life Core-30 (EORTC QLQ-C30) in PPAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
GHS/QoL questions were scored on 7-point scale with scores ranging from 1=Very poor to 7=Excellent.
Scores were linearly transformed to a score range of 0-100.
High score for GHS/QoL scale=better health-related quality-of-life (HRQoL).
CCMD=decrease from baseline (≥10 points) in GHS/QoL scale score, held for at least 2 consecutive assessments/initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Physical Functioning (PF), as Assessed Using EORTC QLQ-C30 in PPAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
PF was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to a score range of 0-100.
High score for PF=high/healthy level of functioning.
CCMD=decrease from baseline (≥10 points) in PF score, held for at least 2 consecutive assessments or initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
OS in FAS
大体时间:From randomization to death from any cause (up to approximately 57 months)
|
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate median OS.
|
From randomization to death from any cause (up to approximately 57 months)
|
|
PFS, as Assessed by the Investigator in FAS
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS.
|
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
Confirmed ORR, as Assessed by an IRF in FAS
大体时间:Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an OR, characterized by CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by an IRF according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
Confirmed ORR, as Assessed by the Investigator in FAS
大体时间:Up to approximately 57 months
|
ORR was defined as the percentage of participants who achieved an OR, characterized by a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Percentages have been rounded off.
|
Up to approximately 57 months
|
|
DOR, as Assessed by an IRF in FAS
大体时间:From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
DOR, as Assessed by the Investigator in FAS
大体时间:From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
DOR was defined as the time from the first occurrence of a confirmed OR, characterized by CR or PR, until the first date of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
CR was defined as disappearance of all target and non-target lesions, normalization of tumor marker level.
Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm.
PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
Median DOR was estimated using the K-M method.
|
From first occurrence of a confirmed OR until the first date of PD or death from any cause, whichever occurred first (up to approximately 57 months)
|
|
TTCD in Cough, as Assessed Using EORTC QLQ-LC13 in FAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Cough was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Dyspnoea, as Assessed Using EORTC QLQ-LC13 in FAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Dyspnoea was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in Chest Pain, as Assessed Using EORTC QLQ-LC13 in FAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-LC13 is a lung cancer-specific instrument consisting of 13 questions: one multiple-item scale assessing dyspnoea (3 items), and 10 single items assessing cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication.
Chest pain was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to score range of 0-100.
High symptom score=high level of symptom severity.
CCMD=increase from baseline (≥10 points) in a symptom score, held for at least two consecutive assessments or an initial clinically meaningful increase above baseline followed by death from any cause within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in GHS/QoL, as Assessed Using EORTC QLQ-C30 in FAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
GHS/QoL questions were scored on 7-point scale with scores ranging from 1=Very poor to 7=Excellent.
Scores were linearly transformed to a score range of 0-100.
High score for GHS/QoL scale=better HRQoL.
CCMD=decrease from baseline (≥10 points) in GHS/QoL scale score, held for at least 2 consecutive assessments or initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
TTCD in PF, as Assessed Using EORTC QLQ-C30 in FAS
大体时间:Up to approximately 57 months
|
TTCD=time from randomization until first CCMD on each respective score.
EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea, vomiting, & pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties).
PF was scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much.
Scores were linearly transformed to a score range of 0-100.
High score for PF=high/healthy level of functioning.
CCMD=decrease from baseline (≥10 points) in PF score, held for at least 2 consecutive assessments or initial clinically meaningful decrease above baseline followed by death within 6 weeks.
K-M method was used to estimate median TTCD.
|
Up to approximately 57 months
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by an IRF in PPAS
大体时间:At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by an IRF, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by the Investigator in PPAS
大体时间:At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by the investigator, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate median PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
OS Rate at 12, 24, 36, and 48 Months in PPAS
大体时间:At Months 12, 24, 36, and 48
|
OS rate at months 12, 24, 36 and 48 was defined as percentage of participants who did not experience death from any cause at the specified timepoints.
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate OS rate.
Percentages have been rounded off.
|
At Months 12, 24, 36, and 48
|
|
Time-to-distant Metastasis (TTDM), as Assessed by the Investigator in PPAS
大体时间:Up to approximately 57 months
|
TTDM was defined as the time from the date of randomization until the date of first documented distant metastasis, as assessed by investigator according to RECIST v1.1, or death, whichever occurred first.
Distant metastasis was defined as any new lesion that was outside of the radiation field.
K-M method was used to estimate median TTDM.
|
Up to approximately 57 months
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by an IRF in FAS
大体时间:At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by an IRF, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
PFS Rate at 12, 18, and 24 Months, as Assessed by the Investigator in FAS
大体时间:At Months 12, 18, and 24
|
PFS rate at 12, 18, and 24 months was defined as the percentage of participants who did not experience PD or death from any cause, as determined by the investigator, at 12, 18, and 24 months.
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first.
PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline).
Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions.
K-M method was used to estimate PFS rate.
Percentages have been rounded off.
|
At Months 12, 18, and 24
|
|
OS Rate at 12, 24, 36, and 48 Months in FAS
大体时间:At Months 12, 24, 36, and 48
|
OS rate at months 12, 24, 36 and 48 was defined as percentage of participants who did not experience death from any cause at the specified timepoints.
OS was defined as the time from randomization to death from any cause.
K-M method was used to estimate OS rate.
Percentages have been rounded off.
|
At Months 12, 24, 36, and 48
|
|
TTDM, as Assessed by the Investigator in FAS
大体时间:Up to approximately 57 months
|
TTDM was defined as the time from the date of randomization until the date of first documented distant metastasis, as assessed by investigator according to RECIST v1.1, or death, whichever occurred first.
Distant metastasis was defined as any new lesion that was outside of the radiation field.
K-M method was used to estimate median TTDM.
|
Up to approximately 57 months
|
|
Number of Participants With Adverse Events (AEs)
大体时间:Up to approximately 24.7 months
|
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product.
|
Up to approximately 24.7 months
|
|
Number of Participants With Cytokine Release Syndrome (CRS)
大体时间:Up to approximately 24.7 months
|
CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells.
Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction.
|
Up to approximately 24.7 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2020年8月24日
初级完成 (实际的)
2025年5月27日
研究完成 (实际的)
2025年7月31日
研究注册日期
首次提交
2020年8月13日
首先提交符合 QC 标准的
2020年8月13日
首次发布 (实际的)
2020年8月14日
研究记录更新
最后更新发布 (实际的)
2026年6月3日
上次提交的符合 QC 标准的更新
2026年5月7日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- GO41854
- 2019-004773-29 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
合格的研究人员可以通过临床研究数据请求平台 (www.vivli.org) 请求访问个体患者水平的数据。
有关罗氏合格研究标准的更多详细信息,请参见此处 (https://vivli.org/members/ourmembers/)。有关罗氏全球临床信息共享政策的更多详细信息以及如何请求访问相关临床研究文件,请参见此处 (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)。
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.